2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
80
Prostatic Neoplasms
57
Carcinoma, Non-Small-Cell Lung
54
Breast Neoplasms
54
Esophageal Neoplasms
48
Rectal Neoplasms
42
Lung Neoplasms
42
Brain Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
33
Head and Neck Neoplasms
33
Gliosarcoma
31
Pancreatic Neoplasms
29
Uterine Cervical Neoplasms
28
Neoplasms
25
Glioma
24
Neoplasm Metastasis
23
Sarcoma
22
Oropharyngeal Neoplasms
21
Esophageal Squamous Cell Carcinoma
20
Melanoma
19
Astrocytoma
18
Adenocarcinoma Of Esophagus
15
Stomach Neoplasms
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Squamous Cell
12
Urinary Bladder Neoplasms
11
Mouth Neoplasms
11
Lymphoma, Follicular
11
Central Nervous System Neoplasms
11
Carcinoma
11
Interventions
Cyclophosphamide
64
Tacrolimus
55
Methotrexate
46
Mycophenolic Acid
39
Cyclosporine
37
fludarabine phosphate
35
Busulfan
35
Antilymphocyte Serum
32
fludarabine
29
Sirolimus
26
Melphalan
23
Peripheral Blood Stem Cell Transplantation
22
Radiotherapy
21
Methylprednisolone
21
Whole-Body Irradiation
19
Filgrastim
17
thymoglobulin
14
Thiotepa
11
Stem Cell Transplantation
10
Rituximab
10
ruxolitinib
9
Granulocyte Colony-Stimulating Factor
9
Prednisone
7
Hematopoietic Stem Cell Transplantation
7
Etoposide
7
Cord Blood Stem Cell Transplantation
7
Alemtuzumab
7
Transplantation
6
Pentostatin
6
Cytarabine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Graft vs Host Disease
×
Radiation
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled